Molecular targeted therapy is the preferred treatment option for patients with advanced or metastatic ccRCC, primarily targeting pathways, such as vascular endothelial growth factor (VEGF), platelet‐derived growth factor receptor (PDGFR), and mechanistic target of rapamycin (mTOR).19 The gene discussed is MTOR; the disease is nonpapillary renal cell carcinoma.